acarbose / Generic mfg. |
ChiCTR-TRC-08000231: Study on the Mechanism of Glucobay in Chinese Newly diagnosed Type 2 Diabetic Patient |
|
|
| Completed | 4 | 880 | | Acarbose: titrated from 50mg qd to 100mg tid, taken for 12 months. Anothore oral Antidiabetic agent can be added after 6 months therapy ;Metformin: titrated from 500mg qd to 1500mg qd, taken for 12 months. Anothore oral Antidiabetic agent can be added after 6 months therapy. | China-Japan Friendship Hospital; Chinese Diabetes Society, Bayer Healthcare Company Ltd. | Newly diagnosed type 2 diabetes | | | | |
| Completed | 4 | 45 | | MMTT will be conducted at baseline. 1w after enrolment MMTT will be conducted togather with acarbose 100mg ,po, once. Then patients will be treated 50mg tid in first 2w and increase to 100mg tid for 4w. After 6w treatment MMTT will be conducted again with acarbose 100mg once. ;Same procedure as group A except OGTT instead of MMTT. ;Healthy subjects with NGT will not be randomly included into group C as control. OGTT will be conducted at enrolment and MMTT will be conducted 1 week apart | Guangdong General Hospital; Bayer HealthCare co., Bayer HealthCare (China) co. | Diabetes | | | | |
ChiCTR-TRC-11001753: The effects of add-on acarbose on the levels of chronic inflammatory state and gut microbiota in patients with type 2 diabetes mellitus |
|
|
| Completed | 4 | 100 | | Acarbose+conventional hypoglycemic therapy ;conventional hypoglycemic therapy | The Second Affiliated Hospital of Dalian Medical University; The Second Affiliated Hospital of Dalian Medical University, Part from a investigator initiative funds for Bayer Health and Pharmaceuticals, Beijing, China. Part from Liaoning Provincial funds for Natural Science, 20062160 | Diabetes Mellitus | | | | |
ChiCTR-TRC-12002271: Efficacy Comparison of Sitagliptin and Acarbose on Drug-Naive 0atients with Type 2 Diabetes: A Prospective, Open-Label, Randomized Clinical Trial |
|
|
| Completed | 4 | 60 | | sitagliptin monotherapy ;Acarbose monotherapy | Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University; Level of the institution:, Hospital | Diabetes | | | | |
ChiCTR-TTRCC-13004112: Pharmacometabonomic characterization of Acarbose in subjects with impaired glucose tolerance |
|
|
| Completed | 4 | 50 | | acarbose compared to placebo | Peking University People's Hospital; Level of the institution:, Bayer Healthcare | Diabetes | | | | |
| Completed | 4 | 37 | | 100mg acarbose ;100mg acarbose ;None | Dept. endocrinology, Guangdong Provincial People's Hospital; Dept. endocrinology Guangdong provincial people's hospital, Bayer Pharmaceuticals International Research Foundation | Type 2 diabetes | | | | |
| Completed | 4 | 4100 | | acarbose | The General Hospital of the People's Liberation Army (PLAGH); The General Hospital of the People's Liberation Army (PLAGH), Bayer healthcare | Hypertension and ischemic heart disease | | | | |
ChiCTR-IPR-15006177: The research of the mechanism of postprandial hypotension and acarbose in the treatment in elder diabetes mellitus |
|
|
| Completed | 4 | 90 | | acarbose100mg ;placebo ;N/A | Beijing Hospital of Ministry of Public Health; Beijing Hospital of Ministry of Public Health, Bayer healthcare company ltd | postprandial hypotension | | | | |
2004-002579-17: A double-blind, randomised placebo controlled study of the effects of Acarbose on endothelial function, hemostatic and fibrinolytic plasmatic factors in patients with stable coronary artery disease and either impaired glucose intolerance or newly diagnosed diabetes mellitus |
|
|
| Ongoing | 4 | 50 | Europe | Glucobay 50 / 100, 9835.01.00, | Medizinische Klinik B, Herzzentrum Ludwigshafen | 1. To study the effect of Acarbose treatment on endothelial function as a potential mechanism for the beneficial effects of better postprandial glycemic control in patients with impaired glucose tolerance or newly diagnosed diabetes mellitus | | | | |
2010-020193-42: A comparative study of the effects of Liraglutide and Acarbose on glycaemic control, weight and Health-Related Quality-of-life(HRQOL) in Overweight type 2 Diabetic patients on Oral Hypoglycemic Agents (OHA\'s)+ high doses of insulin. |
|
|
| Ongoing | 4 | 66 | Europe | Victoza (Liraglutide), Glucobay, Victoza (Liraglutide), Victoza, Glucobay, Victoza, Glucobay | Hywel DdA Health Borad | Type-2 Diabetes Mellitus | | | | |
ChiCTR-IPR-15005996: Acarbose for postprandial hypotension patients with abnormal glucose metabolism: a randomized placebo-controlled clinical trial |
|
|
| Not yet recruiting | 4 | 50 | | Placebo ;acarbose | China-Japan Friendship Hospital; Bureau of Health Care for Senior Officials, Health Care for Senior Officials Foundation | postprandial hypotension | | | | |
ChiCTR-OPC-16008152: Effect of glucagon like peptide -1 analogues of obese type 2 diabetic patients with abdominal fat |
|
|
| Completed | 4 | 36 | | Byetta treatment ;Acarbose treatment | Changzhou 2nd Peoples' Hospital Affiliated to Nanjing Medical University; Changzhou 2nd Peoples' Hospital Affiliated to Nanjing Medical University, Provincial innovation team discipline construction project | Obesity, diabetes | | | | |
SUCCESS study, ChiCTR-IPR-14005716: Comparative efficacy and safety of saxagliptin combination therapy with acarbose, or gliclazide modified release (MR), or metformin therapy in drug na?ve patients with type 2 diabetes mellitus (T2DM ) |
|
|
| Recruiting | 4 | 648 | | saxagliptin combination therapy with metformin ;saxagliptin combination therapy with acarbose ;saxagliptin combination therapy with gliclazide MR | China-Japan Friendship Hospital; AstraZeneca Pharmaceutical Co. Ltd, AstraZeneca Pharmaceutical Co. Ltd | Type 2 diabetes mellitus | | | | |
ChiCTR2000040826: A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment |
|
|
| Completed | 4 | 90 | | Acarbose tablets orally (100 mg/tablet, Bayer, Leverkusen, Germany) 3 times each day with 100 mg each time ;vildagliptin tablets orally (50 mg/tablet, AstraZeneca, Cambridge, London, England) 2 times each day with 50 mg each time ;saxagliptin tablets orally (5 mg/tablet, AstraZeneca, Cambridge, London, England) one time each day with 5 mg each time | Affiliated Hospital of Qiingdao University; Affiliated Hospital of Qiingdao University, Self-financing | Type 2 diabetes mellitus | | | | |
ChiCTR-IPR-17014233: saxagliptin protects early nephropathy of type 2 diabetes by increasing SDF-1α level: A mechanistic study |
|
|
| Recruiting | 4 | 160 | | saxagliptin ;acarbose | Tianjin Medical University Metabolic Diseases Hospital; Tianjin Medical University Metabolic Diseases Hospital, Tianjin Medical University | Diabetic nephropathy | | | | |
| Recruiting | 4 | 60 | | acarbose monotherapy ;DPP-4i monotherapy | Second Affiliated Hospital of Third Military Medical University; Second Affiliated Hospital of Third Military Medical University, National Natural Science Foundation of China | Diabetes mellitus | | | | |
ChiCTR1800017878: Evaluation of blood glucose fluctuation and hypoglycemic effect of dapaglifozin and acarbose in the treatment of type 2 diabetes with CGMS |
|
|
| Recruiting | 4 | 90 | | dapaglifozin ;acarbose | The Second Hospital of Changzhou, affiliated to Nanjing Medical University; Level of the institution:, Patients self-care after signing informed consent | type 2 diabetes | | | | |
ChiCTR1800019724: Efficacy and safety of dapagliflozin and acarbose in type 1 diabetes mellitus |
|
|
| Not yet recruiting | 4 | 62 | | dapagliflozin 10mg qd ;Acarbose 50mg tid | Department of Endocrinology, the First Affiliated Hospital of Shantou University Medical College; The First Affiliated Hospital of Shantou University Medical College, Shantou University Medical College Clinical Research Enhancement Initiative | Type 1 diabetes mellitus | | | | |
ChiCTR1900022751: Efficacy of Dapagliflozin and Acarbose in Patients with Type 2 Diabetes Mellitus Uncontrolled on Metformin Monotherapy: A Multi-centre Randomized Controlled trial |
|
|
| Recruiting | 4 | 128 | | Dapagliflozin(Anda don) 10mg once after breakfast increase Metfomin 500mg twice after breakfast and dinner,if glucose controls poor,metformin can be added to 1000mg twice after breakfast and dinner. ;Acarbose (Bai Tang) 50 mg three times at the same time of three meals increase Metfomin 500mg twice after breakfast and dinner,if glucose controls poor,metformin can be added to 1000mg twice after breakfast and dinner and Acarbose can be added to 100mg three times at the same time of | Zhujiang Hospital, Southern Medical University; Zhujiang Hospital, Southern Medical University, Self-financing | Type 2 diabetes | | | | |
ChiCTR1900023470: Study for dapagliflozin on glomerular hyperfiltration and visceral fat redistribution in patients with newly diagnosed type 2 diabetes mellitus |
|
|
| Not yet recruiting | 4 | 50 | | Dapagliflozin ;Acarbose | Tianjin Metabolic Diseases Hospital; Tianjin Metabolic Diseases Hospital, Self-financing | Type 2 Diabetes Mellitus | | | | |
GVASA, ChiCTR1900021337: The difference of glucose variation between acarbose and sitagliptin as add-on therapy in the elderly patients with type 2 diabetes in China inadequately controlled with pre-mixed insulin twice daily : a multi-center, randomized, parallel-group, open-label trial |
|
|
| Not yet recruiting | 4 | 150 | | Acarbose ;Sitagliptin | Beijing Hospital; Beijing Hospital, BAYER Company | Type 2 diabetes | | | | |
ChiCTR2000038346: Clinical trial of the effect of three different preparations of acarbose chewable tablets/tablets/capsules on the postprandial plasma glucose flucturation in type 2 diabetes |
|
|
| Not yet recruiting | 4 | 24 | | 50mg chewable tablets/50mg tablets/50mg capsules ;50mg capsules/50mg chewable tablets/50mg tablets ;50mg tablets/50mg chewable tablets/50mg capsules | Jinan Central Hospital; Hangzhou Sino-US East China Pharmaceutical Co., Ltd, 浙江省杭州市拱墅区莫干山路866号 | type 2 diabetes | | | | |
| Recruiting | 4 | 432 | | Insulin / metformin + acarbose chewable tablets ;Insulin / metformin | The First Affiliated Hospital of Zhengzhou University; Hangzhou Sino-US East China Pharmaceutical Co., Ltd., Hangzhou Sino-US East China Pharmaceutical Co., Ltd. | type 2 diabetes | | | | |
ChiCTR2000030267: A double-blind, double dummy, randomized controlled trial for the efficacy and safety of miglitol 50 mg with acarbose 50 mg in the treatment of newly diagnosed overweight /obese type 2 diabetes patients. |
|
|
| Recruiting | 4 | 250 | | Miglitol 50mg tid, oral; Acarbose mimetic tablets, 50mg tid, oral ;Acarbose 50mg tid, oral; Miglitol simulating tablets, 50mg tid, oral | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Lunan Beite Pharmaceutical Co., Ltd. | Type 2 diabetes | | | | |
ChiCTR1900025357: A randomized open parallel controlled study for reversing diabetes by reducing liver fat deposition |
|
|
| Not yet recruiting | 4 | 600 | | basic medication + Dapagliflozin ;basic medication + Acarbose | The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University, Self-raising | type 2 diabetes | | | | |
| Completed | 4 | 157 | US | Acarbose | Oregon State University | Healthy Volunteers | 12/22 | 02/23 | | |
ChiCTR2400084794: Efficacy and Safety Analysis of Combined Therapy with Glargine Insulin, Liraglutide, and Metformin in Type 2 Diabetes |
|
|
| Completed | 4 | 87 | | After 7-10 days of intensive insulin pump treatment, the combination of insulin glargine, metformin hydrochloride and liraglutide was given; After 7-10 days of intensive insulin pump therapy, metformin hydrochloride, daglipzin and acarbose were given combined therapy | Guangrao County People's Hospital of Dongying city; Department of Endocrinology, Guangrao County People's Hospital of Dongying city, Department of Endocrinology, Guangrao County People,s Hospital of Dongying city | Type 2 Diabetes | | | | |
ChiCTR2000034289: A phase IIIa multi-center, randomized, double-blind, double simulation, parallel controlled trial for the efficacy and safety of Mulberry Twig Alkaloid Tablet in the treatment of type 2 diabetes mellitus |
|
|
| Completed | 3 | 600 | | Treatment period: 0-24 weeks, Mulberry Twig Alkaloid Tablet + Acarbose Tablet simulator ;Treatment period: 0-24 weeks, Mulberry Twig Alkaloid Tablet simulator + Acarbose Tablet | Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences; Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Self-raised funds | Type 2 Diabetes Mellitus | | | | |
NCT05629806: Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes |
|
|
| Recruiting | 3 | 50 | RoW | Metformin plus pioglitazone, Acarbose | Nanjing First Hospital, Nanjing Medical University | Type 2 Diabetes, Blood Glucose Fluctuation | 05/23 | 05/23 | | |
| Terminated | 3 | 341 | Europe | Acarbose, Glucor 50 mg, Prandial insulin, Rapid acting insulin analog | Assistance Publique - Hôpitaux de Paris | Gestational Diabetes Mellitus in Pregnancy | 08/23 | 02/24 | | |
2016-001986-10: Non-inferiority Between Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus: a Randomized Multicenter and Prospective Trial Non-infériorité du traitement par Acarbose versus Insuline Prandiale pour le Traitement du Diabète Gestationnel chez la femme enceinte : étude randomisée multicentrique prospective |
|
|
| Not yet recruiting | 3 | 1780 | Europe | Tablet, Solution for injection | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS | Pregnant women with Gestational Diabetes Mellitus (GDM) Diabète gestationnel, Pregnant women with Gestational diabetes mellitus (GDM) Diabète Gestationnel chez la femme enceinte, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
ChiCTR-TRC-11001534: Efficacy and Safety of Acarbose Chewable Tablets in Type 2 Diabetic Patients- randomized positive controlled double-blinded and double-dummy multicenter clinical trial |
|
|
| Completed | 2 | 234 | | acarbose 50mg (50mg each tablet) plus one dummy acarbose chewable tablet thrice daily ;acarbose chewable tablet 50mg (50mg each tablet) plus one dummy acarbose tablet thrice daily | West China Hospital, SCU; Biological engineering institute Co., Ltd, Hangzhou pharmaceutical Group; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd; 866# Moganshan Road, Hangzhou City, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd | type 2 diabetes mellitus | | | | |
ChiCTR-OPC-15006702: The Clinical Efficacy and Safety Studies of Sanye Tablets Treatment of Type 2 Diabetes Mellitus and Hyperlipidemia |
|
|
| Not yet recruiting | 2 | 48 | | Sanye Tablets + Acarbose Simulation Agent ;Sanye Tablets Simulation Agent + Acarbose Simulation Agent ;Acarbose +Sanye Tablets Simulation Agent | Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine, The central government funding for 4.7441 million yuan, according to the regulations of the contract that project tasks, to local investment 5 million yuan, enterprises (units) self-raised 7.5 million | Type 2 Diabetes Mellitus and Hyperlipidemia | | | | |
2022-000157-87: HypoBar I: Delaying intestinal glucose absorption to ameliorate post-bariatric hypoglycaemia. A randomized cross-over clinical trial. HypoBarI: Reduceret risiko for lave blodsukre efter fedmekirurgi ved forsinkelse af tarmens glucoseoptagelse. Et blindet kontrolleret klinisk lodtrækningsforsøg. |
|
|
| Not yet recruiting | 2 | 16 | Europe | acarbose, Tablet, Film-coated tablet, Glucobay, invokana | Hvidovre Hospital, Hvidovre Hospital | Post-bariatric hypoglycaemia, Low blood glucose in patients submitted to bariatric surgery., Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] | | | | |
| Active, not recruiting | 2 | 320 | Europe | EMP16-120/40, MR orlistat 120 mg, Conventional orlistat 120 mg,, Xenical, EMP16-60/20, Placebo | Empros Pharma AB, CTC Clinical Trial Consultants AB | Overweight or Obesity | 11/23 | 03/24 | | |
NCT05487859: Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC) |
|
|
| Not yet recruiting | 2 | 24 | US | Acarbose Tablets | University of Alabama at Birmingham | Kidney Cancer | 10/25 | 10/25 | | |
| Completed | 1 | 20 | | Three leaves tablet vs acarbose | the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine; The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, National special projects for major new drugs created by Ministry of Science and Technology | diabetes mellitus | | | | |
| Completed | 1 | 60 | | isophane protamine biosynthetic human Insulin 70/30 (Novo Nordisk) injected subcutaneously 30 minutes pre-meal plus acarbose (Bayer) 50mg, 1/noon; ;isophane protamine biosynthetic human Insulin 70/30 (Novo Nordisk) injected subcutaneously 30 minutes pre-meal plus acarbose (Bayer) 50mg, 3/day ;isophane protamine biosynthetic human Insulin 70/30 (Novo Nordisk) injected immediately pre-meal plus acarbose (Bayer) 50mg, 3/day. | Department of Geriatrical Endocrinology, Chinese PLA General Hospital; Bayer company, bayer company | type 2 diabetese | | | | |
ChiCTR-TRC-13003820: Glucose fluctuation and its influence on flow mediate dilation after different interventions in the patients with impaired glucose regulation: A Prospective, Randomized, Controlled Trial |
|
|
| Completed | 1 | 300 | | Diet and exercise interventions ;Diet, exercise and acarbose interventions ;Diet, exercise and Probucol interventions | West China Hospital, Sichuan University; West China Hospital, Sichuan University, Science and Technology Bureau of Sichuan Province, China; Bayer; Shandong Qilu Pharmaceutical Co., Ltd.; Medtronic, Inc. | Diabetes | | | | |
ChiCTR-IIR-17011903: The desiagn and evaluation standard of bioequivalence trail of acarbose tablet in Chinese volunteers |
|
|
| Recruiting | 1 | 48 | | crossover design | Phase I clinical study room of The Third Xiangya Hospital of Central South University; The Third Xiangya Hospital of Central South University, NA | NA | | | | |
ChiCTR-IIR-17013918: The design and evaluation standard of bioequivalence trail of acarbose tablet in Chinese volunteers (two) |
|
|
| Recruiting | 1 | 16 | | different dose of acarbose | The Third Xiangya Hospital of Central South University; The Third Xiangya Hospital of Central South University, NA | NA | | | | |
ChiCTR1800015795: The design and evaluation standard of bioequivalence trail of acarbose tablet in Chinese volunteers (three) |
|
|
| Recruiting | 1 | 12 | | the different time to take drug | The Third Xiangya Hospital of Central South University; The Third Xiangya Hospital of Central South University, NA | NA | | | | |
ChiCTR1900021914: Pivotal Bioequivalence Study of Acarbose Tablets in Healthy Volunteer |
|
|
| Not yet recruiting | 1 | 60 | | Sucrose-Sucrose+TEST 100mg-Sucrose-Sucrose+CONTROL 100mg ;Sucrose-Sucrose+CONTROL 100mg-Sucrose-Sucrose+TEST 100mg | West China Hospital, Sichuan University; West China Hospital, Sichuan University, From Sponsor | None, Healthy adults | | | | |
| Completed | 1 | 45 | | Phase I: took sucrose water orally alone in fasting state; Phase II: took sucrose water and the test preparation simultaneously; Phase III: took sucrose water and the reference preparation simultaneously. ;Phase I: took sucrose water and the test preparation simultaneously in fasting state; Phase II: took sucrose water and the reference preparation simultaneously; Phase III: took sucrose water orally alone. ;Phase I: took sucrose water and the reference preparation simultaneously in fasting state; Phase II: took sucrose water orally alone; Phase III: took sucrose water and the test preparation simultaneously. | Phase I Clinical Trial Research Center of Xiangya Hospital Central South University; Jiangsu Deyuan Pharmaceutical Co., Ltd., fully self-financing | Diabetes | | | | |
CORRECT, NCT02587741: Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens |
|
|
| Recruiting | 1 | 600 | RoW | Metformin, gliclazide modified release tablets, acarbose, Lantus, Novomix30 | Third Affiliated Hospital, Sun Yat-Sen University | Diabetic Retinopathy | 07/23 | 07/25 | | |
GUTPCO, ChiCTR-TRC-14005075: The ameliorating effect of gut microbiota-targeted nutritional intervention on metabolic dysfunction in PCOS patients |
|
|
| Recruiting | N/A | 60 | | Whole grains, traditional Chinese medicinal foods and prebiotics diet ;acarbose+Whole grains, traditional Chinese medicinal foods and prebiotics diet | Shanghai First People's Hospital, Shanghai Jiao Tong University; Shanghai First People's Hospital, Shanghai Jiao Tong University, Self-funding | polycystic ovary syndrome | | | | |
| Completed | N/A | 30 | | Acarbose+routine diet guidence for diabetes patients ;Acarbose+whole grains, traditional Chinese medicinal foods and prebiotics diet | Shanghai Jiao Tong University; Shanghai Jiao Tong University, National Nature Science Foundation | Type 2 Diabetes | | | | |
ChiCTR-IOR-15006941: Comparative Study on the Influence on Blood Glucose Fluctuation of DPP-4 Inhibitor or Acarbose for T2DM Patients with Inadequately Controlled with insulin |
|
|
| Recruiting | N/A | 100 | | add on vildagliptin 50mg bid ;add on acarbose 50mg tid | The second people's hospital of Shenzhen; Shenzhen 2nd People's Hospital, self-financing | Type 2 Diabetes mellitus | | | | |
ChiCTR1800015195: Saxagliptin up-regulates nesfatin-1 secretion and inhibits erythrocyte aldose reductase activity in newly diagnosed type 2 diabetes |
|
|
| Completed | N/A | 46 | | Saxagliptin ;acarbose | Jiangsu Jiankang Vocational College; JIANGSU JIANKANG VOCATIONAL COLLEGE, college level | diabetes | | | | |
ChiCTR-IPR-17011855: Application of metformin in treatment of non-dementia vascular cognitive impairment |
|
|
| Recruiting | N/A | 100 | | metformin and donepezil, ;acarbose and donepezil | Tianjin First Center Hospital; Tianjin First Center Hospital, department of neurology | vascular cognitive impairment | | | | |
ChiCTR-INR-16008440: A randomized controlled clinical studies of Sancailianmei Particles for the Treatment of Newly Diagnosed Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | N/A | 120 | | Sancailianmei particle ;acarbose | Teaching Hospital of Chengdu University of Traditional Chinese Medicine; Chengdu university of traditional Chinese medicine, Special project funds | type 2 Diabetes Mellitus | | | | |
FLAT, NCT03805191: A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients |
|
|
| Recruiting | N/A | 900 | RoW | | Qilu Hospital of Shandong University, Bayer | Type 2 Diabetes Mellitus, Poor Glycemic Control | 11/20 | 12/22 | | |
ChiCTR1900027394: Possible efficacy and mechanism of siglitine in diabetic peripheral neuropathy |
|
|
| Recruiting | N/A | 50 | | Sitagliptin ;acarbose | South Hospital of Fujian Provincial Hospital; Fujian Medical University, Fujian medical university sailing fund | diabetic peripheral neuropathy | | | | |
| Recruiting | N/A | 60 | RoW | extracorporeal shock wave lithotripsy and endoscopic drainage of the main pancreatic duct, ESWL, ERCP, pancreatic enzyme(Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose Tablets, Glucophage, Glimepirde Tablets) | Changhai Hospital | Pancreatitis, Chronic, Exocrine Pancreatic Insufficiency, Abdominal Pain, Cholangiopancreatography, Endoscopic Retrograde | 11/23 | 11/23 | | |
ChiCTR2100053801: Effects of interaction between gut microbiota and gut brain axis regulated by nutrition on metabolism and reproductive endocrine disorders in polycystic ovary syndrome |
|
|
| Recruiting | N/A | 240 | | Dietary fiber ;Acarbose+Dietary fiber ;Semaglutide ;Dulaglutide | Shanghai First People's Hospital; Shanghai First People's Hospital, Shanghai Jiaotong University Medical-Engineering Cross Research Fund | polycystic ovary syndrome (PCOS) | | | | |
Sancai relieves diabetes, ChiCTR2400086469: Clinical efficacy and related mechanism of Sancai Lianmei granules in remission of early type 2 diabetes mellitus based on traditional Chinese medicine combined with high-throughput sequencing technology |
|
|
| Recruiting | N/A | 84 | | Control of blood glucose with Sancai Lianfang oral traditional Chinese medicine formulation; Control of blood glucose with Acarbose oral medication | Affiliated Hospital of Chengdu University of Traditional Chinese Medicine; Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Sichuan Provincial Administration of Traditional Chinese Medicine | type 2 diabetes | | | | |
voglibose/metformin / Generic mfg. |
VMGMProtocol, NCT05688332: Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients |
|
|
| Not yet recruiting | 3 | 118 | NA | Voglibose + Metformin, Glibenclamide + Metformin | University of Zambia, University Teaching Hospital, Lusaka, Zambia | Diabetes Mellitus Type 2 Without Complication | 12/23 | 01/24 | | |
miglustat / Generic mfg. |
2006-005842-35: Efficacy and safety of treatment with N-butyl-deoxynojirimycin (NB-DNJ-miglustat) in patients with Niemann-Pick disease type C. |
|
|
| Ongoing | 3 | 25 | Europe | ZAVESCA, ZAVESCA | Dipartimento di Pediatria Universita, di Napoli Federico II | NIEMANN-PICK DISEASE TYPE C | | | | |
| Recruiting | 3 | 30 | RoW | Miglustat, Zavesca | Tehran University of Medical Sciences, Mashhad University of Medical Sciences, Kashan University of Medical Sciences | GM2 Gangliosidosis, Supportive Care | 12/24 | 12/24 | | |
ROSSELLA, NCT04808505: A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 |
|
|
| Recruiting | 3 | 36 | Europe, US, RoW | Cipaglucosidase alfa, ATB200, Miglustat, AT2221 | Amicus Therapeutics | Glycogen Storage Disease Type II Infantile Onset | 04/27 | 04/27 | | |
2006-004661-34: Evaluation d’un traitement par miglustat (Zavesca®) chez les patients atteints de mucopolysaccharidose de type III (maladie de Sanfilippo).Essai thérapeutique de phase IIb randomisé en aveugle contre placebo. |
|
|
| Ongoing | 2 | 24 | Europe | ZAVESCA, ZAVESCA, ZAVESCA | HOSPICES CIVILS DE LYON | Mucopolysaccharidose de type III | | | | |
2010-024647-32: Combined enzyme enhancement therapy (EET) and enzyme replacement therapy (ERT) in patients with Pompe disease |
|
|
| Ongoing | 2 | 12 | Europe | ZAVESCA, ZAVESCA | UNIVERSITA, DEGLI STUDI DI NAPOLI FEDERICO II | Patients with Pompe Disease (Type II Glycogenosis) on therapy with Enzyme Replacement Therapy (ERT) for at least 6 months | | | | |
2019-002827-14: Phamacological study to test safety of miglustat in patients with SPG11 Studio sperimentale per valutare la sicurezza della somministrazione di miglustat in soggetti con paraparesi spastica di tipo 11 |
|
|
| Not yet recruiting | 2 | 10 | Europe | Miglustat Gen.Orph 100 mg, capsule rigide, [Miglustat Gen.Orph 100 mg, capsule rigide], Capsule, hard, MIGLUSTAT GEN.ORPH - 100 MG - CAPSULA, RIGIDA - USO ORALE - BLISTER (OPA/ALLU/PVC) - 84 CAPSULE | IRCCS Fondazione Stella Maris, IRCCS Fondazione Stella Maris, Tom Wahlig Stiftung Foundation | Spastic paraparesis type 11 (SPG11), caused by mutations in spatacsin protein, is characterized by the association of peripheral neuropathy, parkinsonism, ataxia, cognitive impairment, hypotrophy of the corpus callosum and retinal degeneration. The disease progresses with degeneration of motor and cognitive functions up to total dependence on caregivers. At the moment there are no therapies capable of modifying its natural history and progression. Paraparesi spastica di tipo 11 (SPG11) è la forma di paraparesi spastica autosomica recessiva più frequente dovuta a mutazioni della proteina spatacsina. E' caratterizzata dall’ associazione di neuropatia periferica, parkinsonismo, atassia, deficit cognitivo, e degenerazione retinica. La malattia progredisce con degenerazione delle funzioni motorie e cognitive fino alla totale dipendenza dai caregivers. Al momento non vi sono terapie capaci di modificarne la storia naturale e la progressione., SPG11 is a rare, uncurable neurodegenerative disease characterized by weak and stiff legs, ataxia, dementia with progressive loss of autonomy. La SPG11 è una malattia genetica del cervello e dei nervi caratterizzata da debolezza e rigidità degli arti, parkinsonismo, disequilibrio, e perdita di autonomia ed è senza cura., Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT02675465 / 2015-004798-34: First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221 |
|
|
| Completed | 1/2 | 29 | Europe, US, RoW | ATB200, AT2221, Miglustat | Amicus Therapeutics | Pompe Disease | 07/24 | 08/24 | | |
BBDF101-01, NCT05174039: An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of CLN3 Disease |
|
|
| Active, not recruiting | 1/2 | 6 | US | Miglustat 100Mg Oral Capsule | Beyond Batten Disease Foundation, Theranexus | Batten Disease | 05/24 | 08/24 | | |
NCT06121011: A Global Prospective Observational Registry of Patients With Pompe Disease |
|
|
| Recruiting | N/A | 500 | Europe, US | Cipaglucosidase alfa, ATB200, Pombiliti, Miglustat, AT2221, Opfolda, Alglucosidase alfa or Avalglucosidase alfa, Myozyme, Lumizyme, Nexviazyme, Nexviadyme, Untreated | Amicus Therapeutics | Pompe Disease | 12/34 | 12/34 | | |
acarbose/orlistat (EMP16) / Empros Pharma |
2019-004545-32: Lean Efficacy Phase IIa Proof of concept trial (LEAAP). A multi-centre, double-blind, placebo controlled, randomised study in overweight and obese patients during twenty-six weeks, investigating the effect of EMP16-02 on body weight, safety and clinical biomarkers |
|
|
| Not yet recruiting | 2 | 156 | Europe | EMP16-02 120/40, EMP16-02 150/50, Capsule | Empros Pharma AB, Empros Pharma AB | Obesity Fetma, Obesity Fetma, Body processes [G] - Metabolic Phenomena [G03] | | | | |
2022-003320-40: A 26-week, double-blind, randomized study in participants with overweight or obesity investigating the added contribution of acarbose in EMP16 on efficacy, safety and tolerability |
|
|
| Not yet recruiting | 2 | 320 | Europe | EMP16, MR orlistat, Capsule, Xenical®, Alli® | Empros Pharma AB, Empros Pharma AB | Obesity Fetma, obesity Fetma, Body processes [G] - Metabolic Phenomena [G03] | | | | |
NCT06013163: A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers |
|
|
| Recruiting | 1 | 20 | Europe | Xenical® vs EMP 22, Part I, EMP 22 vs Xenical®, EMP 16 vs Xenical®, Part II | Empros Pharma AB, CTC Clinical Trial Consultants AB | Overweight or Obesity | 12/24 | 12/24 | | |